Two Onc Docs

This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending.

Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patients and clinicians, and strives to keep healthcare human. 

This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo. 

Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer.

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.

The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).

Today we will be focusing on exciting data to come at the ASCO Annual Meeting in 2026 in Chicago, with a special focus on GU sessions, educational sessions & med ed sessions.

This week’s episode will be focusing on Von Willebrand disease (VWD), a highly testable bleeding disorder. We will go over all the important details on the diagnosis, types of VWD as well as treatment.

Today’s episode is focusing on the highest yield facts about Aplastic Anemia. This will include the mechanism of AA, diagnostic work-up, treatment of AA, and the evolution of clones including PNH.

Today’s episode is focusing on what you need to know regarding metastatic bladder cancer, with 2026 updates. This will include the need to know treatment options and toxicities for metastatic urothelial carcinoma, and also discuss the management of upper tract + variant non-urothelial histology.

Today’s episode is focusing on what you need to know regarding localized bladder cancer, with 2026 updates. This will include the need to know pathology, presentation, diagnostic work-up, staging, and treatment options. 

This week’s episode will be focusing on how we met, the future of the podcast, and why we picked heme/onc. This is a very different style of episode and a special once because this month is our 4 year anniversary of Two Onc Docs! And we will back to our regular programming next week with overdue updates on Bladder Cancer.